Following the announcement of a collaboration with NVIDIA to introduce a Gen AI and advanced software-defined architecture for medical imaging in endoscopy, LTTS shares saw a 1.10 per cent increase. The joint development by LTTS and NVIDIA aims to create a scalable platform for the medical sector, offering features such as image processing pipeline, noise reduction, edge and contrast enhancement, and texture and color improvement.

This software-defined architecture is designed to enhance visualization for image processing and AI-based decision-making support, particularly in polyp detection and classification. Shanker Trivedi, Senior Vice President of Enterprise Business at NVIDIA, expressed that the collaboration offers value to the medical technology industry by expediting the development of AI-enabled, software-defined medical devices.

At 11.40 am on the BSE, LTTS shares were up by 1.10 per cent to ₹4,502.90.